Immpact Bio USA, a biotech startup focused on treatment for solid tumors, closed its Series A financing round at $18 million on Tuesday.

The Camarillo company was founded in 2017 in an Israeli incubator, with the core of its technology stemming from research conducted by two professors, Gideon Gross and Zelig Eshhar...

Join our Membership to get the full story.


Are you a current Member? Sign In